December 6, 2005

Kel's Candles

Kel makes candles.

Occasionally Kel makes candles for charity.

This time she is making one for Adventures In Autism and the Autism Research Institute.

"You can help prevent, diagnose & treat autism in children through your purchase of an Austism Research Soy Candle. For every one you buy, $5 goes to Adventures in Autism and $5 goes to The Autism Research Institute, a non-profit organization studying the causes of autism & methods of preventing, diagnosing & treating autism & other behavioral disorders of childhood."
Kel is a good woman.

December 5, 2005

NAA Autism Confrence DVDs

From the National Autism Association:

National Autism Conference DVDs are now available!

From cutting-edge research of environmental toxins to dietary interventions, legal and legislative strategies to sensory integration, the world’s most renowned experts gathered to share their knowledge and expertise with parents and practitioners last month in Myrtle Beach, South Carolina.

If you were unable to attend, you can now bring the conference home to you by purchasing individual presentations or an entire set of DVDs.

Also available is our official 327 page 2005 National Autism Conference Program book containing speaker presentations. It comes with a free NAA book bag and conference t-shirt.

Click here for more information.


Speakers include:

KEYNOTE SPEAKER
Frank Lawlis, PhD

FEATURED SPEAKERS

Mark Blaxill, MBA
Jeffrey Bradstreet, MD, FAAFP
Rashid Buttar – DO, FAAPM, FACAM, FAAIM
Vince Carbone, PhD
Boyd E Haley, PhD
Andrew J Wakefield, MD

SPECIAL GUEST SPEAKER
David Kirby - Author of Evidence of Harm

BREAKOUT SPEAKERS

Tim Adams
Lynne Arnold
Mary Bolles
Cathi Browder
Julie A. Buckley, MD, FAAP
Thomas M. Burbacher
Beth Clay
Ashley Collins
Phillip C. DeMio, MD
Richard Deth, PhD
Jerry Evans
Carolyn Gammicchia
David Geier, PhD
Mark Geier, MD, PhD
Caroline Gomez, PhD
Doreen Granpeesheh, Ph.D., B.C.B.A.
Cindy L. Griffin, HD (R.Hom.), DSH-P, DIHom
Devin Houston,PhD
Bryan Jepson, MD
Sandra Jill James, PhD
John Kernohan
David Kirby
Jorgen Klaveness
Arthur Krigsman, MD
Roger Kendall, PhD
Michael Lang, PhD
Connie Mathis, PhD
James Neubrander, MD
Mary Beth Palo
Seth Pearl, DC CCN CNS
Lyn Redwood, RN, MSN, CRNP
Adrienne Rousseau
Karyn Seroussi
Selwyn Super, PhD
Sue Tanner
Sherri Tenpenny, DO
Anju Usman, MD
Debbie Wardell

Think Autism. Think Cure.

From A-CHAMP

A NEWS ALERT FROM A-CHAMP... PLEASE POST AND FORWARD

The CBS Evening News is planning to run a two part report on Monday and Tuesday at 6:30pm Eastern that will explore the "myth" that antiperspirants are linked to breast cancer. Rumors of such a link have long circulated on email. However, the rumors have been dispelled by the antiperspirant industry, the FDA and others. Now, according to new and original research done by CBS News Correspondent Sharyl Attkisson, we learn that an antiperspirant-breast cancer link has not been conclusively ruled out, after all. We understand the distinction since this is similar to the government's autism study findings. Up until now, the government and industry had implied or claimed that the breast cancer link had been definitively ruled out.

Those of you who have followed Sharyl's coverage of the autism/mercury debate know that she is a very thorough investigative reporter who doesn't just accept industry and government reassurances. There is a new Executive Producer for the CBS Evening News who will take control in early January. This development may make it possible for reporters like Sharyl, who continues to have an interest in the autism/mercury story, to develop more original, important, relevent stories on various medical fraud and danger issues.

If the Evening News management gets good feedback on this report, it will help these new managers measure the importance and relevance of such stories to many viewers. The antiperspirant/breast cancer series should also be available online (both in video and printed form). Networks measures interest, in part, by how many clicks they get on these Web items as well as viewer email feedback afterward.

Please take a moment AFTER Sharyl's report (hopefully tonight and tomorrow night), to go to www.cbsnews.com and click on the story and send a message asking for continued coverage of this type of story and mention your interest for continued coverage on the autism/mercury controversy.

Below is a link to one of Sharyl Attkisson's earlier stories.
CBS News Online
Mercury Concerns


Thank you,
A-CHAMP

A Reminder to Shop Online and Support My Blogging

Shop through my new fund raising portal and sleep tight knowing that half of the money brought in will be going to the Autism Research Institute.

TACA's Adopt A Family Campaign

ANNOUNCING TACA's HOLIDAY ADOPT A FAMILY CAMPAIGN


Talk About Curing Autism (TACA) is pleased to announce its first annual Adopt-A-Family Holiday Campaign! The holiday season is a happy time filled with warmth, love, generosity and hope – and it is through the special holiday generosity of the Northrop Grumman Corporation that we are able to launch this program.

TACA will be adopting approximately 20 families to help provide the things that will make this holiday special. We will be providing holiday gifts for your children, assistance with special needs such as diapers, groceries, vitamin supplements, etc., and the delivery of a special holiday dinner. Holiday giving will be valued at approximately $200 and will be based on family need and family size.

Apply to be Adopted – Deadline December 14, 2005

If you are a family in need, we will do our best to make 2005 a special holiday season for your family. To qualify, you must:

* Be a TACA member
* Have at least one child with autism
* Live in California
* Be recommended by a TACA coordinator

Please Send the Following Information to Your Local TACA Coordinator:

* Your name, address, and telephone number
* The number of children in your family and their ages (please include some ideas of what they might enjoy for the holidays.)
* Information about your child with autism and their special needs.
* A brief statement on your need this holiday season.
* Whether you are being considered for another adopt-a-family program

TACA Coordinators:

Orange County Lisa Ackerman tacanow@cox.net

Greater Los Angeles Area Debbie Gonzalez bluerus@hotmail.com

San Fernando Valley Moira Giammetteo moira@netzero.com

San Diego County Becky Estepp restepp@sbcglobal.net

Inland Empire Tami Duncan TACAInlandEmpire@aol.com

Central California Lynne Arnold lynne@autisminterventioncentralca.org

Family applications will only be accepted by e-mail.


Join TACA in Making This Holiday Season One to Remember:


Your help will allow us to reach more than the 20 families we are budgeted for:

* Sign up to be a delivery person, shop for the family, and experience the joy of helping others in your area.
* Enjoy your holiday even more by knowing you have made a difference through adopting a family yourself (guidelines below)
* Donate cash or in kind items to the TACA Adopt-A-Family Campaign. You can do this via mail (see address below) or via online at http://www.tacanow.com/shop.htm.

To help please contact Lisa Ackerman at (949) 640-4401 or e-mail tacanow@cox.net.

Adopt-A-Family Guidelines:


* Call (949) 640-4401 or email tacanow@cox.net to register to Adopt-A-Family.
* Purchase gifts for each child. You are not obligated to spend more than $25 for each gift.
* Purchase a gift certificate from a grocery store chain. The dollar amount should be at least $15 for each family member regardless of age.
* Make plans to prepare or purchase a holiday dinner for your family.
* Call your family no later than December 20 and make arrangements to drop off your gifts.
* Call or email tacanow@cox.net TACA and let us know that you have dropped off gifts to your family and share the story of giving during this holiday season.

Special note: if funds received exceed number of qualified families we will continue this program throughout the year to assist families in crisis.

Special thanks to Debbie Gonzalez and Northrop Grumman Corporation for their assistance in making this happen! We truly appreciate the support and the desire to help TACA families in need. HAPPY HOLIDAYS!

Autistic Teen Makes Film About Autism

Autistic license: Teen filmmaker sheds light on his own disorder
By Tenley Woodman
Monday, December 5, 2005

It’s not that unusual for a teen, especially one from California, to be a budding filmmaker. But Taylor Cross, 17, turned his camera on a subject few directors have touched: the mind of the autistic child.

Cross’ 10-minute film “Normal People Scare Me,” which will be shown tonight at the Flutie Bowl in Boston, shows nonautistics what it is like to live with autism.

“Pretty much I’ve been living in a cave for several years, except for the autisic kids,” said Cross during his visit to Boston last week.

Autism is a developmental disorder that alters a person’s social interaction and communication skills and is typically diagnosed in early childhood.

According to the National Institutes of Health and the Centers for Disease Control and Prevention, autism affects one in 166 births.

Cross was diagnosed at age 6. Doctors told his mother that he might never walk or talk.

Eleven years later, the high school junior is trying to turn his short documentary into a feature film with the help of Joey Travolta, owner of Entertianment Experience and the older brother of actor John.

“Make no mistake about it, we have pulled each other’s hair out (at times). It has not been easy,” said Keri Bowers, Cross’ mother. “Taylor looks damn good in life because he works at it.”

Cross interviewed dozens of kids with autism and their parents. Among them was world-class surfer Izzy Paskowitz, who discussed his frustration with his son’s disorder.

“It would be difficult for other kids. It would be and it is. You can imagine another teen in this situation and he’s not autistic. How would he feel?” Cross said.

Though Cross attends regular classes, he has few friends without autism. He said he chooses to hang out with autistic kids, who vary in functioning levels from verbal to nonverbal.

“I think I understand what’s been going on in the head,” he said. “It’s a comfort level.”

Cross has never been invited to a birthday party, play date or engagement by a peer without autism. Those he interviewed have had similar experiences.

“They don’t judge each other,” Bowers said.

Cross, an avid fan of film and video games, hopes to pursue film as a career. In “Normal People Scare Me” he interviewed the dean of New York University’s film program.

Though his path to success has not been easy, Cross said he believes others can make it further than he has.

“When it comes to that, work on it on your own terms. Try to reach out, because it will make you more insecure if you don’t,” he said.

A film about siblings of autistic kids is in preproduction and will be directed by Cross’ younger brother Jace, 10.

To learn more about Taylor Cross’ projects, go to www.artistsforautism.com

“Normal People Scare Me” will be screened at The Flutie Bowl, Lucky Strike, 145 Ipswich St., Boston. Tonight, 6-11 p.m. Tickets are $100, with all proceeds benefiting the Doug Flutie Jr. Foundation for Autism.

Autistic 15-Year-Old Tasered At School

Autistic 15-Year-Old Tasered, Arrested At Florida School
November 30, 2005

FT. MYERS, Fla. -- A school resource officer is being accused of excessive force after using a taser on an autistic student. Now, that boy's mother says a misunderstanding has left her child confused and bruised.

Dennis Caliguri, 15, has bruises to show for what happened when he encountered a school resource officer and his taser. Investigators said Dennis was so violent and out of control that it took five faculty members to restrain him and the taser was used to calm him down.

Dennis is autistic and functions at the level of a six-year-old. But at 5'8" tall and 220 pounds, his mother, Susan Caliguri, said he is big but harmless. So she was shocked to get a call from Cypress Lake High School saying he was acting out. When she got to the school, she was horrified.

"It was a nightmare. They had him handcuffed, his legs were tied, he was on the ground. They had four sheriffs on top of him. I mean, he is bruised down his back, they were stunning him and he was already down. He couldn't do anything," she said.

Susan calls it excessive force, but the Lee County Sheriff's Office said the taser was the only way to calm him down.

"The matter is that the deputy, if he is that tired out and he has a fear of being overpowered, his weapon being taken away from him, he has to be able to overpower and be able to take control of the situation," said Charles Ferrante, Lee County Sheriff's Office

School administrators said Dennis got upset after being told not to come to school one day last week. He misunderstood and thought he was in trouble and started throwing papers.

Despite his mother's concerns, Dennis was arrested and charged with disturbing the peace and resisting arrest.

December 4, 2005

Pentagon Withheld Anthrax Vaccine Injury Information

An Incomplete Picture
Despite promises that hospitalizations after anthrax vaccinations would be reported, the Pentagon withheld data on more than 20,000 cases.
BY BOB EVANS
December 4, 2005
Daily Press - Hampton Roads, Virginia

First of four parts
bevans@dailypress.com

The Pentagon never told Congress about more than 20,000 hospitalizations involving troops who'd taken the anthrax vaccine, despite repeated promises that such cases would be publicly disclosed.

Instead, a parade of generals and Defense Department officials told Congress and the public that fewer than 100 people were hospitalized or became seriously ill after receiving the shot from 1998 through 2000.

They also showed Congress written policies that required public reports to be filed for hospitalizations, serious illnesses and cases where someone missed 24 hours or more of duty.

But only a sliver of those cases were reported, while the rest were withheld from Congress and the public, records obtained by the Daily Press show.

Critics of the vaccine, veterans' advocates and congressional staffers say the Pentagon's deliberate low-balling of hospitalizations helped persuade Congress and the public that the vaccine was safe.

Keeping the actual number of illnesses secret contributed to a shorter list of government-recognized side effects for the drug, giving patients and physicians a false idea of what might constitute a vaccine-related illness or problem. Doctors are expected to know the full list of side effects and alert federal drug safety officials whenever they see a repeat of those symptoms.

Repeated evidence of the same adverse side effect after a vaccination is one of the most telling signs of a systematic problem with a drug or vaccine, as opposed to a coincidental relationship, vaccine safety experts say.

During the Daily Press' investigation of the vaccine and its effects, the newspaper found three cases of amyotrophic lateral sclerosis - ALS, or Lou Gehrig's disease - that the military hadn't reported. The disease destroys muscles and nerves, is always fatal and rarely hits people younger than 45.

One of the three cases involves Navy Capt. Denis Army of Virginia Beach. Army died in 2000, after developing symptoms less than a week after his first anthrax vaccination - and a few days before his 45th birthday. His widow filed the first public acknowledgement of his death and its temporal connection to the vaccine this year. That occurred after she talked to a Daily Press reporter and learned that she could file a report with the federal Vaccine Adverse Event Reporting System, or VAERS.


SAILOR'S DEATH NOT REPORTED BY MILITARY

Navy Petty Officer 2nd Class Kristin Shemeley died of ALS in 2001, at 29. Her symptoms began about two months after her third shot, a sworn legal document detailing her illness says.

Before Shemeley died, she spent 14 months in Walter Reed Army Medical Center in Washington, where she was regularly visited by high-ranking military officers, said her mother, Ginger Shemeley of Quakertown, Pa. She says her daughter repeatedly told those generals and admirals that she was suffering because of the vaccine and even pleaded with one of them to stop giving it to troops. Several of those generals and admirals had promised Congress that such cases would be publicly reported to VAERS.

The military never filed a VAERS report on Kristin Shemeley. Ginger Shemeley filed one after her daughter died.

Col. John Grabenstein, director of the military's vaccine agency, said no one from the military intentionally misled Congress or the public. He said the 20,765 hospitalizations merely followed vaccinations in time, without documented proof of a cause-and-effect relationship.

He said a statistical analysis showed that those who'd been vaccinated weren't more likely to be hospitalized or likely to seek medical treatment than those in the military who hadn't been vaccinated from 1998 through 2000.

Some medical experts say this approach doesn't adequately address the problems of many people who report illnesses after anthrax vaccination. That's because the approach is limited to comparing rates of illness involving one symptom or disease - instead of the complex combination of symptoms and illnesses that many veterans report after getting their shots.

The data that the Daily Press used to document the underreporting of hospitalizations came from a report that Grabenstein supplied in response to the newspaper's request. It's never been made public until today.

It covers 1998 through 2000, when the Pentagon did detailed evaluations every three months to compare hospitalizations, clinic visits and medical treatment data for those who'd been vaccinated, compared with troops who hadn't. This quarterly analysis stopped and hasn't been done since, Grabenstein said.

The practice of not reporting all hospitalizations continues.

Quarterly analysis of the vaccine's effects ended just as the nation's only manufacturing site for the drug regained its license. That was in 2002, after federal inspections found many safety and other problems that prompted a shutdown and renovation that began in early 1998.

The company's current manufacturing techniques provide greater potency compared with earlier versions of the drug, said the Government Accountability Office, Congress' investigative arm. The manufacturer, BioPort Inc., says there's no difference in the drug made since 2002 that might cause health problems.


TOP GENERAL NOT TOLD MONITORING TO END

The decision to discontinue the quarterly health monitoring program means that the biggest gap in research about the vaccine remains: There are no systematic long-term studies of the health of those who've taken the drug. Most studies that the Pentagon cites as support for the vaccine's safety involve monitoring that lasted days to a few months.

None lasted as long as five years, the minimum length of time recommended by a nationally recognized panel of scientists assembled by the Institute of Medicine in 2002. The institute is a nonprofit organization that provides expert advice to Congress and other government agencies.

After the quarterly reviews of the vaccine's effects stopped, more than a million troops were forced to take the vaccine - until a federal judge ruled last year that the drug had never been adequately licensed for protection against anthrax use in warfare.

He ordered the military to make vaccination voluntary. The Pentagon is appealing that ruling. Lawyers argued the case Thursday, and a decision is expected by February.


VACCINE MONITORING STILL IMPORTANT

Grabenstein said he decided to halt the quarterly studies after consulting the chairman of the Institute of Medicine panel and its staff, and with doctors affiliated with the military. He acknowledged that he didn't consult the general who ultimately was responsible for the anthrax program.

The chairman of the institute panel, Brian Strom, said he didn't recall what was discussed at the time about the quarterly reports. But he said, "I think they should continue to be using it," in case there's a problem.

Another panel member, Linda Cowan, said she's sure the committee expected quarterly reviews to continue and pointed to a number of the panel's recommendations and findings that she said clearly contradicted Grabenstein's interpretation of its report.

Strom and Cowan emphasized that they thought the vaccine was still safe.

Beth Clay isn't so sure. She directed the staff of Congress' House Government Reform Committee investigation into the anthrax vaccine from 1998 to 2001. She continued working on the subject as a congressional staff member through 2003, after her Republican boss was no longer chairman of the committee.

Clay said the military's decision not to report all the hospitalizations gave the public and Congress a rosier picture of the vaccine than it deserved.

"We were never given this data," she said. "Had we seen this, the committee would have had significant questions" and would have demanded more information about the program.

After reviewing the report obtained by the Daily Press, Clay said it raised several questions about the vaccine's safety. She said Congress was never told about the detailed level of data in the report but was assured regular monitoring of the vaccine and its health effects would continue.

Terminating the quarterly reviews would seem to break those promises, she said. "It's just appalling that they didn't keep up with this," she said.


LINK BETWEEN VACCINE, HOSPITALIZATIONS?

Steve Robinson is executive director of the National Gulf War Resource Center, a lobbying and advocacy group for veterans. He said he was stunned when he learned that the reviews had stopped: "They track the flu vaccine and not the anthrax vaccine, which is totally crazy to me."

He said discovery of the hospitalization data showed that the Pentagon couldn't be trusted to monitor the vaccine's safety.

"You can't let Enron investigate Enron, and you can't let DOD (the Department of Defense) investigate DOD," he said. "We work with the people who have been hurt by this vaccine every day."

No one knows how many, or how few, of the 20,765 hospitalizations are directly attributable to the vaccine. Ruling out certain illnesses, such as broken bones or injuries from falls or other accidents, might appear a safe bet. But military doctors have documented cases where broken bones and other injuries from falling were the result of vaccine-induced loss of consciousness affecting the nervous system - sometimes beginning mon thsaftervaccination.BRBRThe difficulty of figuring out what's related and what isn't is why safety officials encourage people to file reports even if they're not sure.


WHY PENTAGON DIDN'T FILE HOSPITAL REPORTS

Still, medical experts consulted by the Daily Press said it's unlikely that the vast majority of the 20,765 hospitalizations resulted from the vaccine. They said that if all hospitalizations had been filed with VAERS, it would have overloaded the system and caused problems for experts trying to analyze the data.

Grabenstein said those were among the reasons that the full number of hospitalizations was not reported. Another reason, he said, was that examinations of the data showed that if there were adverse effects from the vaccine, they were so infrequent, they weren't detectable by statistical analysis. Doing this type of analysis - instead of simply reporting the incidents to VAERS - provided a more definitive look at the health effects of the vaccine, he said. As a result, "we decided not to file" public reports about all hospitalizations, he said.

Those considerations weren't relayed to Congress or the public.

During the years covered by the hospitalization report obtained by the Daily Press, dozens of sick veterans who'd received the shot went to Capitol Hill, complaining of various health problems. Some got the shot for the 1991 Persian Gulf War, in which the vaccine had its first widespread use. Others were members of the military forced to take the shots under a mandatory program that began in 1998.

Their complaints had common themes: Fatigue. Chronic pain in joints and other symptoms of arthritis. Tingling in their feet, arms and hands. Mental lapses. Often, more than one of the symptoms were present, making diagnoses difficult.

Sympathetic doctors testified that these complaints were indicative of autoimmune problems, in which the body's natural protective mechanisms go haywire and start attacking healthy cells and tissue. The doctors said that could result if the vaccine overstimulated the vets' immune systems. The vaccine primes the system to develop protection against anthrax.

Bewildered and sometimes-angry members of Congress asked how many vets were affected. Pentagon doctors and generals used the cases reported to VAERS - fewer than 100 hospitalizations or other "serious events" from 1998 to 2000 - or said the number was so small, it couldn't be detected.


VACCINE REPORTS ARE FIRST LINE OF DEFENSE

The two sets of numbers for how many hospitalizations followed the shot come from a comparison of two sets of data kept by three federal agencies.

The Food and Drug Administration and the Centers for Disease Control and Prevention maintain the only database open to public inspection, VAERS. VAERS is the nation's first line of defense in identifying possible problems with vaccines after they've been licensed, said Susan Ellenberg, who led the FDA's efforts to monitor vaccine safety from 1993 to 2004.

During congressional testimony before the House Government Reform Committee's Subcommittee on National Security, Veterans Affairs and International Relations in July 1999, Ellenberg explained how and why the system worked.

VAERS was established to help identify and head off problems once a vaccine is licensed and more people are taking it, she said. The few hundred people typically involved in vaccine or drug testing and licensing trials can't mimic the diversity of age, race, gender and other biologic variables encountered once the vaccine gets widespread public use, she explained.

Reports to VAERS by civilian doctors and hospitals are mostly voluntary, based on suspicion of a connection between an illness or injury and a vaccination, Ellenberg told Congress.

Doctors and others are encouraged to file a report, known as a VAERS-1, even when they aren't sure there's a cause and effect, she said. That's because VAERS requires as many reports of problems as possible, so experts can identify possible patterns and investigate further, she said.


GENERALS' TESTIMONY PROMISED REPORTS

During the same congressional hearing, Lt. Gen. G. Robert Claypool - then the deputy assistant secretary of defense for health operations policy - assured Congress that military doctors, hospitals and medical officials were filing VAERS-1 forms, too.

And, he said, they were expected to report even more cases than civilians - including all hospitalizations.

"The duty to report adverse medication events has been codified for many years," Claypool testified. "The joint regulation requires submission of a form VAERS-1 for all adverse events resulting in more than 24 hours of lost duty time or any period of hospitalization. These requirements represent a higher standard than in comparable civilian community health care settings."

There was no mention that the word "all" didn't mean all hospitalizations.

Two months later, Lt. Gen. Ronald R. Blanck, then the Army's surgeon general and the top Pentagon official responsible for the anthrax vaccine program from 1998 to 2000, gave similar assurances to Congress.

He said, "We have a reporting system that when either of those two criteria are met, that is, either a patient is hospitalized following an anthrax immunization or misses duty because of it for greater than 24 hours, we have an active reporting system. That must be reported to us. We, in turn, report it to the Food and Drug Administration, and they have a group that reviews those reactions."

Clay and other congressional aides say these assurances came in private, too. "We had lengthy conversations that they were supposed to report," she said.

But the numbers reported were very low. And the Pentagon stuck with them for years to persuade the public that the shot was safe.

In December 2003, Pentagon officials conducted a news conference to rebut a judge's ruling that the shots had been given illegally and that troops had been used as "guinea pigs." Grabenstein was asked whether he had "any data on the numbers of people who have had bad adverse reactions to the vaccine and would have required hospitalization."

He said that only 69 hospitalizations had been reported to VAERS for the anthrax vaccine from 1998 through 2000. A panel of civilian experts had analyzed each, he said, and decided that 11 were results of the shot. The 69 cases were "a complete, exhaustive list of what was reported," Grabenstein said.

Grabenstein told the Daily Press that his statement wasn't misleading. He said no one should expect all hospitalizations after vaccination to be reported to VAERS - despite the Pentagon's written policies - because the number included cases unrelated to the vaccine, sometimes years after vaccination.

He said, "The simple answer is it's so obvious, it's never appeared in the memo."


NO EXCEPTIONS NOTED IN POLICY MEMOS

The memo, "Policy for Reporting Adverse Events Associated With the Anthrax Vaccine," serves as the standing order for all military personnel. It reads: "For the purposes of reporting anthrax vaccine adverse events, a Form VAERS-1 must be completed and submitted using service reporting procedures for those events resulting in a hospital admission or time lost from duty for greater than 24 hours or for those events suspected to have resulted from contamination of a vaccine lot."

The memo lists additional circumstances requiring a report, but nothing that would permit excluding hospitalizations after vaccination. It refers to the Pentagon's formal regulations, which don't include the exclusions that Grabenstein cited.

The data on all hospitalizations after anthrax vaccination comes from the Pentagon's Defense Medical Surveillance System, or DMSS. This computerized tracking system pulls medical records for every shot, clinic visit, hospitalization or other instance of medical treatment for active-duty military personnel.

Experts in health care and statistics say it's one of the most important medical databases in the world. That's because of its precision, its millions of patients, and the diversity of drugs and vaccines used by the armed forces. By design, it's more complete and accurate than VAERS. Unlike VAERS, its data isn't open to the public.


EXPERTS: NO EXCUSE FOR SECRET DATA

The Institute of Medicine report that Grabenstein cited as supporting the vaccine's safety and his decision to end the quarterly monitoring program also says the DMSS database should be open to researchers outside the government, with precautions to protect the privacy of individuals' health records.

This hasn't been done. Grabenstein said the military had not been able to figure out how to protect individuals' health records and make it work.

Strom of the institute panel and other experts say it should not be that difficult. "There's no excuse," he said. "We use these kinds of data sets in Medicaid and Medicare data all the time. There are technological solutions."

Cowan, another member of the panel, said the institute's recommendation was based, in part, on the military saying it couldn't afford all the analysis that the data was good for: "That way, you get the most of what the American people have invested in."

Strom said keeping the data from the public only bolstered the perception that the military was hiding the truth about the vaccine.

Walter Schumm is a professor of family studies and an expert on statistical methods at Kansas State University. He said he and other researchers would love to get the DMSS data. He's a retired Army colonel who's spent more than a decade using statistical analysis to examine the vaccine's safety - after friends and others in uniform began complaining about health problems after the shots.

Schumm has used other data made public on the anthrax vaccine to publish several scientific papers that poke holes in the safety assertions made by Pentagon doctors and researchers.

Good science involves people with different approaches to the same problem having a chance to test their theories, Schumm and others say. Their findings might cement the safety assertions, he said, but no one knows for sure until the military loosens its hold on the facts and data.

He said, "If you let independent people have the data, you risk losing control. In combat, letting things get out of control gets people killed, so loss of control is a very sensitive issue. I'm just sure they're trying to protect their program."

Cardiologist Criticizes Merck Behavior

Cardiologist Criticizes Merck Behavior
By THERESA AGOVINO
AP Business Writer Sat Dec 3, 6:12 PM ET

HOUSTON - A prominent cardiologist testifying against Merck & Co. accused the drugmaker Saturday of engaging in scientific misconduct, suppressing clinical evidence and stifling medical discourse as it promoted the painkiller
Vioxx.

Dr. Eric Topol, chairman of the cardiovascular medicine department of the Cleveland Clinic, called certain aspects of Merck's behavior "repulsive" and "appalling" during his three-hour videotaped deposition.

Topol said Vioxx can cause heart attacks any time after a patient begins taking it, and that its risks were apparent as early as 1999, when the drug was approved. Vioxx was removed from the market last year after a study showed it doubled patients' risk of heart attacks and strokes after 18 months of use.

"Vioxx's risk has been evident since trails were conducted in 1999 and all the way through the time of withdrawal in September 30, 2004," Topol said.

This is the first federal trial over Vioxx; Merck has already lost one state trial over the drug and won another, but it still faces about 7,000 lawsuits and analysts estimate its liability could reach $50 billion.

The jurors who heard Topol's testimony Saturday will be asked to decide if the drug contributed to the fatal heart attack suffered by Richard "Dicky" Irvin in May 2001. The 53-year old former manager of a seafood wholesaler had been taking Vioxx for about a month for back pain.

Merck argues that the drug wasn't responsible for Irvin's death, saying problems with Vioxx surface after 18 months of use, not one month, and alleging that plaque in Irvin's artery ruptured and caused the heart attack, not the drug.

Both sides in the case are under a gag order.

Topol said the concerns about Vioxx caught his eye after he read an article about a study released by Merck in 2000 that found patients taking Vioxx had five times the rate of heart attacks as those taking naproxen, another pain reliever. In the article, Merck explained differences found in that study by saying naproxen is cardioprotective. Topol said naproxen wasn't associated with such properties.

"To all of a sudden ascribe some type of magical protective effect (to naproxen) without any basis is not acceptable," he said.

When he compared the U.S.
Food and Drug Administration records of the study with the data in the
New England Journal of Medicine article, Topol said he found several discrepancies. In particular, he said, the number of deaths and heart attacks were higher in the FDA data. He called the discrepancies "scientific misconduct."

Topol also said that the company had conducted a trial in 1999 comparing Vioxx to a placebo and nabumetone, another pain reliever, that found Vioxx caused a "760 percent excess rate of heart attacks," but that the study was never published.

In 2001, as Topol was preparing to have published an article he had written highlighting cardiovascular risk from Vioxx, he received a visit from Dr. Alise Reicin, vice president of clinical research at Merck Research Labs.

According to Topol, Reicin told him he would be "embarrassed" if he published the article because he didn't have all the data.

After the article was published, he said, Merck sent letters to doctors all over the country saying his analysis was wrong. He was said Merck also attempted to "trash" others who criticized Vioxx.

Topol also testified that Merck's former chairman Raymond Gilmartin approached the chairman of the Cleveland Clinic to complain about his frequent criticism of Vioxx. Topol referred to that action as "repulsive."

Topol, who subpoenaed by the plaintiff to testify, declined to comment Saturday but through a spokeswoman said he only wants to be an advocate for scientific integrity and patient safety and doesn't want to be involved in litigation.

Merck filed a motion to exclude Topol's deposition but only succeeded in getting certain parts eliminated from what the jury saw. For example, at one point during the deposition, Topol read an e-mail he wrote to a colleague which said he was "bothered by the continued outrageous lies of Merck with their full page, multiple ads that 'they publish everything'...."

Broken Mirror Neurons

'Copying' nerves broken in autism
BBC News

Abnormal activity in neurons that help individuals imitate others may underlie some of the social deficits found in autism, US researchers believe.

A Nature Neuroscience study found autistic children had less brain activation in an area involved in understanding others' state of mind.

The degree of activation of the 'mirror neurons' housed in this area correlated with measures of social impairment.

The lower the activation, the stronger the impairment the children had.

Mirror neurons

Autism affects a person's ability to communicate with others and to respond appropriately to environmental cues.

In animals, mirror neurons have been shown to fire both when the animal observes another performing an act and when they perform the same act themselves.

Dr Mirella Dapretto and colleagues studied the brain activity patterns of 10 children with autism as the children either imitated facial gestures or passively watched facial gestures.

The facial gestures reflected emotions including fear, anger, sadness and happiness.


The general notion of linking mirror neurons with the social deficit in autism is quite reasonable
Professor Michael Rutter from the Institute of Psychiatry

The researchers compared these outcomes with those of 10 children of the same age and IQ but who did not have autism.

Although the autistic children were able to perform the task, they had lower activation in a brain area containing mirror neurons - the inferior frontal gyrus pars opercularis - both when watching and imitating facial gestures, compared to the other children.

The children with autism also had reduced activity in emotion centres of the brain - the insula and the amygdala.

Dr Dapretto, of University California, Los Angeles, said: "Our findings suggest that a dysfunctional mirror neuron system may underlie the social deficits observed in autism.

"Together with other recent data, our results provide strong support for a mirror neuron theory of autism. This is exciting because we finally have an account that can explain all core symptoms of this disorder."

Caution

The researchers believe that children with autism must use other parts of the brain in order to be able to perform the task that they tested.

For example, the autistic children might pay more attention to visual and motor clues without experiencing the internally felt emotional significance of the imitated facial expression.

Professor Michael Rutter from the Institute of Psychiatry, London, said: "The mirror neurons are interesting and there is some good research in animals looking at how they function.

"The general notion of linking mirror neurons with the social deficit in autism is quite reasonable.

"But we need more research into the brain systems that might be involved. These might involve mirror neurons, but we need more studies."

The National Autistic Society said: "There is strong evidence to suggest that autism can be caused by a variety of physical factors, all of which affect brain development - it is not due to emotional deprivation or the way a person has been brought up.

"We welcome research into all areas which may throw light on the causes behind autism."

Offit's Vaccine Up For Approval by FDA

From John Gilmore at ACHAMP:

A vaccine for rotavirus (Rotateq) developed by Merck, the Children's Hospital of Philadelphia and Paul Offit, America's most quoted promoter and apologist for the vaccine industry, will be considered for licensure on December 14 and by the Vaccines and Related Biological Products Advisory Committee of the Center for Biologics Evaluation and Research of the FDA.

Offit and his partners Merck and the Children's Hospital of Philadelphia, first received a patent for a rotavirus vaccine in 1994. Offit later voted to add rotavirus vaccine (a variety from Wyeth not Merck) to the recommended schedule of vaccines when he was a member of the FDA's Advisory Committee of Immunization Practices. Despite his ownership of a rotavirus vaccine patent Offit saw no need to recuse himself from several votes on adding rotavirus to the schedule, which is one of the last steps to inclusion in the mandatory schedules, and a guaranteed market worth billions to a vaccine maker, and comes with complete immunity from lawsuits.

This vaccine was rushed into distribution has quickly shown to cause massive intestinal damage and death in a small but vulnerable subset of children. It was just as quickly removed form the market.

According to the FDA website three of the members of the Committee's members have applied for and received waivers dor potential conflicts of interest

Participation of the public is permitted in this meeting:

Date and Time:
The meeting will be held on December 14, 2005, 9:00 am to 4:30 pm; and on December 15, 2005, 9:00 am to 4:30 pm

Location:
Holiday Inn Select, 8120 Wisconsin Avenue, Bethesda, MD, 20814, 301-652-2000 .

Contact Persons:
Christine Walsh, R.N. or Denise Royster, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512391. Please call the Information Line for up-to-date information on this meeting.

Agenda:
On December 14, 2005, the Committee will hear presentations and make recommendations on the safety and efficacy of a Rotavirus Vaccine manufactured by Merck. On December 15, 2005, the Committee will hear presentations and make recommendations on the safety and efficacy of ZOSTAVAX (Zoster Vaccine Live [Oka/Merck] ) manufactured by Merck.

Oral Presentations:
Between approximately 1:15 and 1:45 pm, on December 14, 2005; and 1:30 and 2:00 pm on December 15, 2005, oral presentations from the public will be scheduled. Those desiring to make formal oral presentations should notify the contact person before December 7, 2005.

RotaTeq®
Paul Offit at The Children's Hospital of Philadelphia developed a vaccine based on a bovine strain of rotavirus (WC-3). Merck is currently running Phase III trials of a modified version of his quadravalent reassortant vaccine.

Aiming to avoid the adverse affects that RotaShield® was associated with, the vaccine is based on a bovine strain of rotavirus. The bovine strain was chosen because it replicates less prolifically in the human gastrointestinal tract than the simian strain used for the tetravalent rhesus reassortant vaccine. [1] Each of the five reassortants consists of the genetic backbone of the bovine virus with an inserted gene coding for a different human rotavirus surface protein. The inserted genes were selected to represent a broad range of serotypes in order to elicit protection against a wide variety of strains.

Genes coding for four VP7 proteins and one VP4 protein are included in the reassortants. Human serotypes G1, G2, G3 and G4 are represented by the four VP7 proteins, and serotype P1a is represented by the VP4 protein. [2]

Initial trials of a similar live quadrivalent human-bovine reassortant vaccine demonstrated promising protection against rotavirus infection. [3] Differing from the Merck vaccine only by the exclusion of serotype G4, this vaccine's results likely mirror the protection that RotaTeq® will afford.

The quadrivalent vaccine, which was delivered to vaccinees in three oral doses at 2, 4, and 6 months of age (identical to the Merck vaccine delivery schedule), showed 74.6% efficacy against any rotavirus infection and 100% efficacy against severe rotavirus infection. No increase in diarrhea, vomiting, fever or irritability was reported as compared to the recipients of the placebo.

The immunogenicity of the quadrivalent vaccine was reflected in an increased ratio of rotavirus specific IgA to total IgA as measured in the vaccinee's stool. [3]

Licensure of RotaTeq® by the FDA is predicted for 2005 if Phase III trials are successful.

December 2, 2005

NYT Vaccine Liability Editorial and Editorial Reply by NAA

Op-Ed Contributor
A Shot at Justice
By DIRK OLIN
Published: November 30, 2005

PRESIDENT Bush's recently proposed $7.1 billion plan for pandemic flu protection is admirably ambitious. It is also remarkably self-defeating in two vital areas: manufacturer liability and victim compensation.

Announcing his proposal at the National Institutes of Health on Nov. 1, the president invoked one of his favorite political demons: "In the past three decades," he said, "the number of vaccine manufacturers in America has plummeted, as the industry has been flooded with lawsuits." So the president's proposal contemplates a ban on lawsuits against vaccine makers, unless plaintiffs can prove willful misconduct. It also provides scant means of redress for the few patients who will inevitably be injured by adverse reactions. And it places legal oversight in the hands of two cabinet secretaries.

But lawsuits are not the reason so few vaccine makers are in business today. Moreover, the existing system for adjudicating vaccine claims is actually working pretty well.

To be sure, vaccine production has a checkered legal history. In 1955, one of the companies that made Jonas Salk's new polio vaccine failed to completely inactivate the embedded virus. A couple of hundred children were permanently paralyzed by inoculation side effects, and a handful died. A jury subsequently found the manufacturer not negligent, but financially liable, thereby casting a pall of uncertainty over vaccine production.

Congress made things worse during the swine flu scare in the mid-1970's. Responding to liability concerns among manufacturers, it declared that any suits would have to be brought against the federal government. When thousands of vaccine recipients suffered nerve and muscle damage, they were able to prevail against the government under a fairly simple liability standard. As a result, pharmaceutical companies feared future exposure to lawsuits under the lower threshold.

But Congress dissipated the legal fog in the 1980's after a wave of claims alleged injury from diphtheria-tetanus-pertussis vaccinations. The 1986 Vaccine Injury Compensation Act created a no-fault system that provides relatively generous payments to victims of specific inoculations recommended by the Centers for Disease Control and Prevention. Special masters at the Court of Federal Claims constitute a vaccine court. The system provides both relief for victims and greater certainty for pharmaceutical companies. (Although claimants are supposed to be able to opt out and bring a suit in state court, such cases face high hurdles - witness the lack of success to date by one group of plaintiffs who claim that inoculations have caused autism.)

Last year, Congress extended the compensation program to include flu shots. But even before that, influenza inoculations did not constitute a trial lawyer boondoggle. A study published in The Journal of the American Medical Association in October found a total of 10 reported cases of flu vaccine litigation during the past 20 years. One case resulted in a $1.9 million award for damages, while the rest were settled for much smaller amounts.

The president is correct that vaccine production in America is anemic. But the main cause is a low profit margin born of high fixed costs and an undependable market, not legal exposure.

In addition to misdiagnosing the problem, the president would misguidedly assign authority for liability determinations to the secretary of health and human services and the attorney general. Yes, the threat posed by a serious pandemic or bioterrorism requires that society recalibrate the balance between plaintiff rights and public safety. But having political appointees serve as arbiters will discourage some Americans from getting shots and thereby undermine the pursuit of universal inoculation.

Moreover, Republicans might ask themselves whether they'd want such determinations made by some future Democratic administration. Would they endorse, say, a Secretary Henry Waxman and an Attorney General Eliot Spitzer exercising similarly autocratic control over such findings?

If the court of claims can't handle the load, we should hire more experts and judges. That's the most sensible means of encouraging manufacturers to make the stuff and the public to take it. An effective pandemic policy must protect pharmaceutical companies from frivolous litigation, but it also must assure the public that the most vulnerable members of our society won't be treated like so many guinea pigs.

Dirk Olin is director of the Institute for Judicial Studies.

------------------------------------------------
re: A Shot at Justice
By DIRK OLIN
Published: November 30, 2005

"...the president invoked one of his favorite political demons: "In the past three decades," he said, "the number of vaccine manufacturers in America has plummeted, as the industry has been flooded with lawsuits." So the president's proposal contemplates a ban on lawsuits against vaccine makers, unless plaintiffs can prove willful misconduct. It also provides scant means of redress for the few patients who will inevitably be injured by adverse reactions. And it places legal oversight in the hands of two cabinet secretaries.

TO THE NEW YORK TIMES:

Dirk Olin's article on the moves to indemnify the vaccine makers because of a possible pandemic makes mention of lawsuits, but that is really not the issue. Mr. Olin is right that studies have shown that drug makers don't want to produce vaccines because the market is so unstable and they're not big profit makers.

In speaking of vaccine injury cases, Mr. Olin notes "...the lack of success to date by one group of plaintiffs who claim that inoculations have caused autism." This may be an aside in the article, but it is actually a very relevant issue in the move to protect the vaccine makers.

More and more parents, doctors, and scientists are claiming that the mercury-based
preservative THIMEROSAL is responsible for an epidemic of neurological disorders among our children. Under the guise of guaranteeing vaccines to fight a possible pandemic, the Congress is frantically working to protect the pharmaceutical industry in the face of mounting evidence that the use of mercury in vaccines has caused an epidemic of neurological disorders.

Mr. Orlin's states that "that the most vulnerable members of our society won't be treated like so many guinea pigs."

Sadly, it's too late for that. During the past 20 years, the autism rate has gone from one in 10,000 to one in every 166 children today. Furthermore, one in every six schoolchildren now has a diagnosis of attention deficit or some other learning disability. This increase directly coincides with the increase in mercury-containing vaccines in the childhood schedule, The best our federal health agencies can tell us is that it's all due to "better diagnosing." This claim is disputed by more and more independent research that shows that thimerosal is responsible for a medical scandal that looms as a welfare disaster. With eighty per cent of autistic Americans under the age of 18, the dramatic impact of this crisis will be felt by taxpayers in the coming years when these autistic children become adults.

In his new book, Evidence of Harm, author David Kirby points out that "...many researchers had sent the company [Eli Lilly] documents dating back to the 1930's, each raising a red flag about thimerosal." (EOH 207-209). Mr. Kirby chronologically lists over 70 years of scientific research on the damaging and deadly effects of thimerosal that was willfully ignored by Eli Lilly and the CDC. http://www.evidenceofharm.com/

Seventy years after the mercury-based preservative thimerosal was invented and put into use, charges that it is responsible for the epidemic increase in autism caused the Centers for Disease Control to direct the Institute of Medicine to present a study in 2004 that showed no connection between mercury and the disorder. Using population studies with easily flawed and manipulated numbers and ignoring the toxicological studies that showed thimerosal is a deadly additive, they hoped to end the controversy. Despite this report, the number of opponents to the IOM Report clearing thimerosal continues to grow.

We are a society with a growing controversy. We need the press to focus on the generation of children with disorders directly associated with exposure to the second deadliest element on Earth.

Anne McElroy Dachel
Media Relations Coordinator
National Autism Association
Chippewa Falls, WI
http://www.nationalautismassociation.org

Articles from Kansas City Reporting on the autism epidemic:

Does danger lurk in that vaccine?
Family’s experience sparked activism
Startling rise in autism stirs questions about the cause

Also see:

http://www.safeminds.org
http://www.nomercury.org

December 1, 2005

Study Looking for Autistic GI Patients

New Study to Evaluate Effect of an Investigational Drug on Gastrointestinal Dysfunction in Children with Autism
Thursday December 1, 10:00 am ET

SACRAMENTO, Calif., Dec. 1 /PRNewswire/ -- The UC Davis MIND Institute is one of twelve trial sites participating in a research study to evaluate an investigational medication for the treatment of persistent gastrointestinal (GI) dysfunction in children with Autism.

Frequently children with autism experience persistent GI problems, ranging from mild to moderate degrees of inflammation in both the upper and lower intestinal tract. These problems have an impact on the autism community, which currently has limited information on the cause and appropriate treatments.

To be considered for participation in the study, and experience some of the following symptoms:

* Chronic diarrhea or constipation
* Bloating
* Gas
* Abdominal pain

Research volunteers will receive study medication and medical care at no cost to the family.

To find out mare about the study as well as additional inclusion/exclusion criteria, please contact Norman Brule, 916-734-7732.